Pilot Study of Neoantigen Profiling in Patients with Melanoma Treated with PD-1 Blockade

General Information Age Group Adults Status Recruiting Protocol Number 16-2427 Background Information This research study is designed to better understand the molecular determinants of response to immunotherapies including pembrolizumab and nivolumab. We hope to learn the relevance of tumor neoantigens in the recognition of cancer cells by the immune system. The ultimate goal is to rank and filter these neoantigens and correlate with response to immunotherapies. Offered At Inova Schar Cancer Institute 8081 Innovation Park Drive Fairfax, VA 22031A department of Inova Fairfax Hospital Eligibility Information >= 18 years Stage III or IV melanoma Underwent treatment with anti-PD-1 therapy (pembrolizumab or nivolumab) for at least 12 weeks with available radiologic response data For patients prospectively consenting able to provide informed consent for blood collection For patients eligible but deceased, a waiver of consent is requested to obtain only existing tissue previously collected for clinical purposes Contact Information Contact Name Kelly Jeffords, CCRP Contact Phone 571-472-0631 Contact Email Send Email